Naoko Takasu (Executive Director of CiRA Foundation). Dr. Steve Hsu-Sung Kuo (Chairman of TCPC)

Key Points

• The CiRA Foundation (CiRA_F) and Transformative Cell Processing Company (TCPC) have signed the letter of intent.
• Leveraging the strength of both Taiwan's semiconductor technology and CiRA_F's medical research, the partnership seeks to present solutions to bring iPS cell therapy from basic research to industrial applications.

Summary

To upgrade the regenerative medicine in Taiwan and advance the cell processing capacity into the international market, CiRA_F and TCPC has signed the letter of intent on 10th, March 2023.
By optimizing processes and reducing costs of manufacturing iPS cells and quality tests, CiRA_F and TCPC aim to provide high quality iPS cells to make iPS cell production affordable medical products.

Background

CiRA_F and National Yang-Ming Chiao-Tung University (NYCU) signed the MOU in 2020, and two of the collaborative research agreements in 2021.
To accelerate the technology development of NYCU, TCPC was founded as a spin-off company of NYCU.
CiRA_F and TCPC are working closely to contribute to the international society with advanced regenerative medicine technology.

Inquiries

The CiRA Foundation
Public Relations Group, Planning Promotion Office
E-mail：contact*cira-foundation.or.jp
(Change * to @.)